Skip to main content
TipRanks
Go Ultimate75% OFF

Arjo AB (ARJO.B) AI Stock Analysis

2 Followers
SE:ARJO.B

Arjo AB

(Nasdaq OMX AB:ARJO.B)

Select Model
Rating:63Neutral
Price Target:SEK 36.00▼(-1.91% Downside)
Action:reiterated
Date:10/24/26

The overall score of 63 reflects a company with positive momentum and a credible profit improvement plan, weighed down by weak underlying profitability and cash generation. The strongest factors are the bullish technical trend and the positive earnings call, which highlighted solid organic growth and a clear EBIT improvement commitment. The primary risks are the low net margin and poor operating cash flow coverage, which make the current P/E of 25.4 appear expensive. The balance sheet is stable, providing a floor for the rating.

Positive Factors
Structural Care DemandUnderlying demand is supported by a growing number of patients requiring care, which can make Arjo’s products relevant across economic cycles. This structural need, combined with its focus on acute and long-term care, supports durable market opportunity and recurring replacement and service demand.
Negative Factors
Compressed ProfitabilityProfitability remains materially below prior years, limiting the earnings produced from Arjo’s revenue base and equity capital. Lower margins can reduce resilience to cost inflation or pricing pressure, while modest ROE suggests the company is not yet converting its capital base into returns as efficiently as before.

Arjo AB (ARJO.B) vs. iShares MSCI Sweden ETF (EWD)

-30%-20%-10%0%10%20%30%SE:ARJO.B+22.51%EWD+16.66%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 856.49M
Dividend Yield
2.59%
Average Volume (3M)
412.38K
Price to Earnings (P/E)
27.6
Beta (1Y)
0.47
Revenue Growth
-0.50%
EPS Growth
-17.58%
Country
Sweden
Employees
7,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

Arjo AB Business Overview & Revenue Model

Company Description

Arjo AB (publ) is a global leader in providing medical devices and innovative solutions tailored for patients experiencing limited mobility and age-related health conditions. Operating across North America, Western Europe, and other international mar...

How the Company Makes Money

Arjo makes money primarily by selling and servicing medical devices and care equipment to healthcare providers (such as hospitals, nursing homes, and other care institutions), typically through a combination of direct sales and distributor channels d...

Arjo AB Earnings Call Summary

Earnings Call Date:Oct 22, 2026(Q3-2026)|% Change Since:31.26%|Next Earnings Date:Jan 28, 2027
Earnings Call SentimentPositive

The call was predominantly positive, supported by 6% organic growth, stronger gross profit and adjusted EBIT, improved reported margins, higher operating cash flow, and lower leverage. Management also highlighted strong momentum in patient handling, North America, and Europe, along with a SEK 350 million EBIT improvement plan. Offsetting issues included higher restructuring costs, weaker quarterly performance in international and distributor-led markets, less favorable working capital, negative investment cash flow, revaluation losses, and uncertainty around the flu season's effect on the fourth quarter.

Positive Updates

Solid Organic Growth
Arjo delivered 6% organic growth in Q3, with positive development throughout all three months of the quarter and momentum carried over from the strong finish to Q2.

Negative Updates

International and Distributor-Led Markets Lagged in the Quarter
International and distributor-led markets did not deliver similarly strong growth during the quarter, although management said they were performing well year-to-date.

Company Guidance

Arjo reiterated a SEK 350 million commitment of profit improvements until H1 2029, described as a SEK 350 million profit improvement it believes it will be able to deliver by mid-2029, with the improvement being EBIT improvement; restructuring costs were “conservatively mentioned,” the company hopes it “will not need all of this,” and “the majority will happen largely over the coming 18 months.” Arjo will report progress every quarter, present new financial targets during Q1 2027, publish the year-end report at the end of January, and report Q1 in April 2027.

Arjo AB Financial Statement Overview

Summary

Arjo's financials show a stable balance sheet with declining leverage, but profitability is a major concern. Margins have contracted significantly from 2021 peaks, with TTM net margin at just 3.2%. Cash flow has recovered from a weak 2022, but operating cash flow coverage of net income remains low at 0.39, indicating weak cash generation quality.

Income Statement

48Neutral

Balance Sheet

62Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue11.12B11.00B11.29B10.98B9.98B9.07B
Gross Profit4.35B4.32B4.91B4.74B4.21B4.21B
EBITDA1.87B1.81B2.03B1.97B1.70B2.03B
Net Income361.00M334.00M498.00M480.00M449.00M742.00M
Balance Sheet
Total Assets15.95B14.98B16.28B16.00B16.17B14.61B
Cash, Cash Equivalents and Short-Term Investments858.00M836.00M892.00M923.00M949.00M757.00M
Total Debt5.35B5.35B5.42B5.49B6.31B5.45B
Total Liabilities7.92B7.52B7.94B8.42B8.54B7.73B
Stockholders Equity8.03B7.46B8.34B7.58B7.62B6.88B
Cash Flow
Free Cash Flow970.00M757.00M838.00M1.38B15.00M974.00M
Operating Cash Flow1.58B1.44B1.52B2.06B915.00M1.73B
Investing Cash Flow-677.00M-705.00M-635.00M-638.00M-902.00M-695.00M
Financing Cash Flow-809.00M-730.00M-907.00M-1.43B136.00M-1.28B

Arjo AB Technical Analysis

Technical Analysis SentimentPositive
Last Price36.70

Price Trends

50DMA30.43Positive
100DMA28.88Positive
200DMA26.93Positive

Market Momentum

MACD1.98Positive
RSI81.71Negative
STOCH71.28Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ARJO.B, the sentiment is Positive. The current price of 36.70 is above the 20-day moving average (MA) of 34.50, above the 50-day MA of 30.43, and above the 200-day MA of 26.93, indicating a bullish trend. The MACD of 1.98 indicates Positive momentum. The RSI at 81.71 is Negative, neither overbought nor oversold. The STOCH value of 71.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ARJO.B.

Arjo AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:ARJO.B against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:ALIF.BSE:ALIF.B74OutperformSEK 22.11B34.4711.32%0.83%1.62%63.45%
SE:ASKERSE:ASKER67NeutralSEK 28.26B37.38―0.53%――
SE:XVIVOSE:XVIVO64NeutralSEK 6.25B48.515.89%―17.83%330.94%
SE:ARJO.BSE:ARJO.B63NeutralSEK 10.00B27.594.65%2.59%-0.50%-17.58%
SE:BACTI.BSE:BACTI.B53NeutralSEK 523.91M83.061.93%―-0.51%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:SEDANASE:SEDANA49NeutralSEK 912.91M-26.45-3.88%―0.42%15.03%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%75%SE:ARJO.BSE:ALIF.BSE:XVIVOSE:BACTI.BSE:SEDANASE:ASKERDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:ARJO.B and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:ARJO.BArjo AB Class B36.707.0923.95%
SE:ALIF.BAddLife AB Class B181.305.132.91%
SE:XVIVOXvivo Perfusion AB198.4033.4020.24%
SE:BACTI.BBactiguard Holding AB14.95-3.80-20.27%
SE:SEDANASedana Medical AB9.19-0.42-4.37%
SE:ASKERAsker Healthcare Group AB73.65-13.13-15.13%

Arjo AB Corporate Events

Arjo Delivers Solid Q3 Growth and Unveils Profitability-Boosting Strategy

Oct 22, 2026

Arjo reported solid third-quarter performance, with net sales rising to SEK 2,849 million and organic growth of 6.0%, supported by improved gross margin and higher adjusted EBITDA and operating profit. North America and Europe delivered more than 6%...

Arjo Reshapes Geographic Segments to Align Reporting With New Operating Model

Oct 20, 2026

Arjo, a global provider of medical equipment and mobility-focused care solutions, designs products that support patient transfers, hygiene, disinfection, diagnostics, leg ulcer treatment, pressure injury and deep vein thrombosis prevention, and medic...

Arjo Sets October 22 Date for Q3 2026 Report and Investor Call

Oct 8, 2026

Healthcare equipment specialist Arjo, which employs around 7,000 people globally and has more than 65 years of experience, provides a broad range of solutions that support safe, dignified care and better outcomes for patients with mobility issues. It...

Arjo Launches New Strategy With 350 MSEK EBIT Improvement Target

Sep 24, 2026

Arjo AB, a global provider of healthcare equipment and mobility-focused care solutions such as patient transfer systems, hygiene and disinfection products, diagnostic tools, leg ulcer treatments and medical beds, is leveraging its nearly 70-year heri...

Arjo Names Polestar Executive Lisa Ekelund as New CFO

Sep 11, 2026

Arjo has appointed Lisa Ekelund as its new Chief Financial Officer and member of the Group management team, succeeding long-serving CFO Christofer Carlsson, who will depart in early 2027. Ekelund, currently CFO of Polestar Nordics and a board member...

Arjo Sets Capital Markets Day to Outline Profitability and Strategy Plans

Sep 1, 2026

Arjo will host a Capital Markets Day for analysts, institutional investors, and media at Epicenter in central Stockholm on September 24, 2026, with the event also streamed live. Presentations will run from 09:00 to 11:30 CEST, be held in English, and...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 24, 2026